chrisvoncsefalvay/vaers-outcomes huggingface dataset:
fever of 102.3; lost sensation in both arms; Lost sensation in both legs; This spontaneous pregnancy case was reported by a consumer and describes the occurrence of PYREXIA (fever of 102.3), SENSORY LOSS (lost sensation in both arms) and SENSORY LOSS (Lost sensation in both legs) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. Last menstrual period and estimated date of delivery were not provided. On 27-Feb-2021, the patient experienced PYREXIA (fever of 102.3), SENSORY LOSS (lost sensation in both arms) and SENSORY LOSS (Lost sensation in both legs). On 28-Feb-2021, SENSORY LOSS (lost sensation in both arms) and SENSORY LOSS (Lost sensation in both legs) had resolved. At the time of the report, PYREXIA (fever of 102.3) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information not provided. Concomitant medications were not provided.
Information has been received from a 20 year old female certified medical assistant with migraines and a history of congenital immunodeficiency abnormality with no "memory cells", fibromyalgia and a full case of varicella at one year who on 13 Oct 2006 was sprayed in the eyes (left greater than right) with Proquad. Concomitant therapy included propranolol HCl and hormonal contraceptives (unspecified). Unspecified medical attention was sought. She flushed her eyes with warm water. She experienced a burning sensation in the eyes that lasted 5 minutes and resolved following flushing. No redness was noted. The patient's physician indicated that the patient "manages most infections' quite well. Her immune status "may be akin to chronic fatigue." There was no product quality complaint involved. Additional information has been requested.
Low-grade fever; Severe joint/muscle aches; Severe joint/muscle aches; Moderate headache; Moderate fatigue; This is a spontaneous report from a contactable nurse. A 53-year-old female patient (not pregnant) received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) second dose, via an unspecified route of administration on 08Jan2021 12:15 at single dose on right arm for COVID-19 immunization. Medical history included hypertension, anxiety and penicillin allergy. Historical vaccine included bnt162b2 for covid-19 immunization. Concomitant medication included acetylsalicylic acid (ASPIRIN), escitalopram, famotidine, losartan and prazosin. The patient experienced low-grade fever, severe joint/muscle aches, moderate headache, moderate fatigue, all on 08Jan2021 17:00 with outcome of recovering. Patient did not receive any treatment. Patient did not experience COVID prior vaccination and did not have COVID tested post vaccination.  Information on Lot/Batch has been requested.
arm soreness; felt hot; I work in construction my next is always sore. The area above collarbone was swollen.; The area above collarbone was swollen; cramping on the left side near the ribcage in the front and back; tightness in my neck; something rubbing against my collarbone; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PAIN IN EXTREMITY (arm soreness), JOINT WARMTH (felt hot), NECK PAIN (I work in construction my next is always sore. The area above collarbone was swollen.), SWELLING (The area above collarbone was swollen) and MUSCLE SPASMS (cramping on the left side near the ribcage in the front and back) in a 38-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.     On 28-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Apr-2021, the patient experienced PAIN IN EXTREMITY (arm soreness), JOINT WARMTH (felt hot), NECK PAIN (I work in construction my next is always sore. The area above collarbone was swollen.), SWELLING (The area above collarbone was swollen), MUSCLE SPASMS (cramping on the left side near the ribcage in the front and back), MUSCULOSKELETAL STIFFNESS (tightness in my neck) and ARTHRALGIA (something rubbing against my collarbone). The patient was treated with IBUPROFEN at an unspecified dose and frequency and PREDNISONE at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (arm soreness), JOINT WARMTH (felt hot), NECK PAIN (I work in construction my next is always sore. The area above collarbone was swollen.), SWELLING (The area above collarbone was swollen), MUSCLE SPASMS (cramping on the left side near the ribcage in the front and back), MUSCULOSKELETAL STIFFNESS (tightness in my neck) and ARTHRALGIA (something rubbing against my collarbone) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: positive (Positive) SARS-CoV-2 test-positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.
Severe hypothyroidism TSH of 69.8, recurrence of Epstein barr,  severe multi system inflammation including kidney, liver, heart and thyroid as well as hands as evidenced by extreme labwork changes. Previously within that year all labwork was completely normal.    No menstrual cycle for 4 months  Extreme cold sensitivity  Hair loss Jaundice scalera  Extreme fatigue  Joint pain Muscle pain and weakness ?Brain fog?    Symptoms persisted 4 months plus and still have not completely resolved even with medication
SORE THROAT; HEADACHE; FEVER; PAIN AT THE INJECTION SITE; VACCINE ADMINISTERED OUTSIDE OF THE 6 HOUR TIME FRAME OF STORAGE CONDITION; OUT OF SPECIFICATION PRODUCT USE; This spontaneous report received from a health care professional concerned a female of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 29-JUL-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported.  On 29-JUL-2021, the subject experienced vaccine administered outside of the 6 hour time frame of storage condition. On 29-JUL-2021, the subject experienced out of specification product use. On an unspecified date, the subject experienced sore throat, headache, fever, and pain at the injection site. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the headache, sore throat, fever, pain at the injection site, vaccine administered outside of the 6 hour time frame of storage condition and out of specification product use was not reported. This report was non-serious. This case, from the same reporter is linked to 20210802801.
Moderate to extensive Orticaria to Trunk, Axillary, and thigh.
Cough, sputum production, with sometimes streaks of blood, rhinorrhea, facial pressure and myalgias; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a patient of unknown age and gender. No information was provided regarding concomitant medications, concurrent conditions or medical history. On or around 04-NOV-2015, the patient was inoculated with zoster vaccine live (ZOSTAVAX) for routine adult health maintenance and for its intended purpose: the prevention of shingles (dose, dose number, route, anatomical site of vaccination, lot # and expiration date were not provided). On an unknown date (reported as shortly after receiving the vaccine), the patient suffered cough, sputum production, with sometimes streaks of blood, rhinorrhea, facial pressure and myalgias. The patient was diagnosed with pneumonia. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient's symptoms had resulted in physical limitations not present prior to using the vaccine. The patient also experienced mental and emotional distress due to resulting physical limitations and seriousness of the patient condition. In addition, the patient sustained severe and permanent personal injuries. Further, the patient had suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. Finally, as direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient had suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of pneumonia was not recovered. The causal relationship between the event and zoster vaccine live (ZOSTAVAX) was assessed as related.  Pneumonia was considered a disabling event by the reporter.  Upon internal review, pneumonia was considered a medically significant event.
On 10/17/2001 Pt developed red area about 2 inches diameter on left upper arm where injection was given. On 10/18/2001 advised to mark around red area. use ice on arm and take Benadryl. On 10/19/2001 PC tp pt red area smaller, getting better.
This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. The patient's concurrent conditions, medical history and concomitant medications were not reported. On 21-JUL-2015, the patient was vaccinated with the first dose of GARDASIL (dose, route of administration, anatomical location, lot number and expiry date were not provided) for prophylaxis. On 04-APR-2019, the patient came to the office for administration of GARDASIL 9 as a second dose (dose, route of administration, anatomical location, lot number and expiry date were not provided) for prophylaxis. No adverse effects were reported.
injection site kind of red; injection site kind of swollen; slight pain at the injection site when she touches it; soreness at the injection site/a little pain at the injection site; A spontaneous report was received from a consumer of 75-years-old  patient concerning self  who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events soreness at the injection site, a little pain at the injection site, injection site kind of red, injection site kind of swollen, slight pain at the injection site when she touches it.  The patient's medical history was not provided. Concomitant medications included blood pressure medication and vitamins. On 3 Feb 2021, prior to the onset of the events the patient received their first of two planned doses of mRNA-1273 (lot/batch: unknown) via unknown route of administration and unknown anatomical location for prophylaxis of COVID-19 infection.  On 3 Feb 2021, the patient experienced the events soreness at the injection site and a little pain at the injection site .  On 17 Feb 2021, the patient experienced the events , injection site kind of red, injection site kind of swollen, slight pain at the injection site when she touches it. Treatment details was not reported.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of events soreness at the injection site and  a little pain at the injection site was considered resolved on 5 Feb 2021. The outcome of event(s),  injection site kind of red, injection site kind of swollen, slight pain at the injection site when she touches it was unknown.
Develop a dark rash on chest , scaley, covers part of pectorial area and has jumped around.
Information has been received from a physician concerning an 18 year old female patient who on 30-APR-2007 was vaccinated with a first dose of Gardasil.  She received her second dose of Gardasil on 12-DEC-2007.   The physician reported that the patient developed a "flare up" of genital warts after receiving the second injection.  The patient reported that the non specific increase in amount of genital warts began about one month after the patient received the first dose of Gardasil on 30-APR-2007.  The physician stated he did not examine the patient and the symptoms were self reported.  Additionally, the patient reported the increase in genital warts to the patient's gynecologist (unspecified name).  No other symptoms and no other information available at the time of this report.  The outcome was unknown.  Additional information has been requested.
Covid Diagnosed with multiple home tests 6/14/22. Cold-like symptoms (congestion, fatigue, minor headache).  Spoke with consulting nurse, then PA via phone, was prescribed Paxlovid 6/15. Most symptoms decreased within two days, other than slight fatigue.
No treatments. Outcomes hair loss,  constant migraines, skin irritation and itching, no milk supply
This spontaneous report as received from a medical assistant refers to an unknown number of patients of unknown age and gender. On unknown dates, the patients received an improperly stored dose of GARDASIL 9 (lot number M016193, expiration date 24-APR-2018, lot number M017983, expiration date 30-MAY-2018) (dose and route not reported). The temperature excursion was 34.02 Fahrenheit for 8 hours. There were no previous temperature excursions. This was reported because of a data logger. No adverse events have been reported.     This is one of several reports received from the same reporter. Additional information has been requested.; Sender's Comments:  US-009507513-1611USA010428.
The injection site is red, sore, redness spreading Down right arm and under right Arm. Took Benadryl & iced side. Redness is better the next day as well as less soreness.
Janssen COVID-19 Vaccine EUA  Fever (not too high - fluctuating around 37 - 37.5 C) , sore body, headaches. Feeling like before you catch a cold. It's been like these for 11 days now. It's too many days now.
Patient received a vaccine on 12-Apr-2022  which had got expired on 07-Apr-2022; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient received a vaccine on 12-Apr-2022  which had got expired on 07-Apr-2022) in a 33-year-old male patient who received mRNA-1273 (Spikevax) (batch no. 070H21A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 12-Apr-2022, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 12-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient received a vaccine on 12-Apr-2022  which had got expired on 07-Apr-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient received a vaccine on 12-Apr-2022  which had got expired on 07-Apr-2022) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications were not reported.  It was reported that total of 173 doses were administered having Lot number has 070H21A.  The dates of administration were 08-Apr-2022, 12-Apr-2022 and 13-Apr-2022 .  No information was reported on date of the storage of vaccine in refrigerator.  Vaccine was expired on 07-APR-2022.  The vial did not undergo any temperature excursions.  Treatment information was not reported.  HCP administer expired vaccine to patients, after the manufacture date of expiration and wanted an assessments on the case.   Most recent FOLLOW-UP information incorporated above includes: On 08-Jun-2022: Follow up received contains non-significant information-Additional Patient identifier were added.
I received a half-dose of Moderna vaccine a week ago. I've been uncomfortable since, with lots of abdomen pain/cramping/nausea & in the evening something of an urge to vomit; luckily I have both dicyclomine & ondansetron. My temp is erratic, chills (especially cold hands) or low-grade fever, with a headache. Dizziness is less, but I still can't focus that well (vision slightly impaired). I've mainly hung out in my bed in my pj's.   I have not felt up to doing tasks like writing checks or doing laundry, and I certainly don't feel well enough to drive.  I hate these vaccines:  I had 3 weeks of suffering the 2 times before when I was vaccinated, with J & J and later with Pfizer.  I assume I have another couple of weeks of suffering with this one.  I have contacted a physician to see if any added medication or supplement is recommended.
Times were approximate listed on the initial sheet. Pt has COVID vaccination and then went in to be observed by school nursing staff. Pt then developed shortness of breath and feeling of her throat being extremely tight. Pt was administer the Epinephrine by the school staff. Then myself and staff went in to assist. Checked vital signs and pt still holding her throat. Pt denies being anxious prior to the shot and has had no adverse reactions in the past. Pt then stated that she felt as though the epinephrine was helping. Assessed throat and the back of her left side of her tongue was slightly swollen. After about 10 minutes she stated that she felt her throat getting very tight again. EMS were then called and pt transported to ER
arm became warm; arm became  pink; arm became inflamed; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (arm became warm), VACCINATION SITE DISCOLOURATION (arm became  pink) and VACCINATION SITE INFLAMMATION (arm became inflamed) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concomitant products included LEVOTHYROXINE SODIUM (SYNTHROID), ATENOLOL and VITAMINS NOS for an unknown indication.    On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 31-Dec-2020, the patient experienced VACCINATION SITE WARMTH (arm became warm), VACCINATION SITE DISCOLOURATION (arm became  pink) and VACCINATION SITE INFLAMMATION (arm became inflamed). On 31-Dec-2020, VACCINATION SITE WARMTH (arm became warm), VACCINATION SITE DISCOLOURATION (arm became  pink) and VACCINATION SITE INFLAMMATION (arm became inflamed) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       Treatment information included warm compress on the arm.   This case was linked to US-MODERNATX, INC.-MOD-2021-014829 (E2B Linked Report). This case was linked to MOD-2021-014829 (Patient Link).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-014829:
Her arm from elbow to shoulder became swollen and red with rash. It is still swollen and rash continued. She is able  to control itch with Benadryl
A 80 y.o. male patient of MD with history of physical deconditioning, recurrent fall with multiple chronic compression fracture presented to Hospital with fall and shortness of breath.   Positive COVID at facility- treatment completed Covid-19 Virus Infection Acute Hypoxemic respiratory failure  Date of onset of symptoms: Unknown Symptoms present on admission: Hypoxemia and cough  Date of covid positive test: 3/16/23 Vaccination status: Vaccinated  Imaging: CT chest moderate to severe emphysema Oxygen requirements on admission: None Current oxygen requirements: None (was on 2L NC) Medical therapy: Continue remdesivir and Decadron. Remdesivir -completed Consultants following: ID Anticipated special isolation end date: 3/26/23 Discontinue Rocephin Trend daily CRP, ferritin, LDH     Mild hyponatremia  Na+ 135 IV Hydration given   Hyperkalemia-resolved K+ 5.3>4.4   Recurrent fall Chronic Fatigue  CT Brain negative for acute findings, stable chronic atrophic changes and small vessel ischemic changes CT Cervical/Thoracic/Lumbar showing chronic unchanged compression fracture deformities T2-L2 Left Humerus negative for acute findings  PT/OT eval and treat  Care management for discharge planing
Vocal Tic. Every few seconds- half hiccup (quick intake of breath).  Nurse heard over phone and was upset.
This spontaneous report as received from a registered nurse refers to unspecified number of patients. On an unknown date, the patients were vaccinated with some improperly stored doses of PNEUMOVAX 23 (dose, route and lot # not reported). No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
Injection site hot; Injection site hard in some places; Injection site size of an orange, red; Arm was sore; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (Injection site hot), VACCINATION SITE INDURATION (Injection site hard in some places), VACCINATION SITE ERYTHEMA (Injection site size of an orange, red) and VACCINATION SITE PAIN (Arm was sore) in an 81-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Jan-2021, the patient experienced VACCINATION SITE WARMTH (Injection site hot), VACCINATION SITE INDURATION (Injection site hard in some places), VACCINATION SITE ERYTHEMA (Injection site size of an orange, red) and VACCINATION SITE PAIN (Arm was sore). At the time of the report, VACCINATION SITE WARMTH (Injection site hot), VACCINATION SITE INDURATION (Injection site hard in some places), VACCINATION SITE ERYTHEMA (Injection site size of an orange, red) and VACCINATION SITE PAIN (Arm was sore) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not provided. Treatment medication included acetaminophen.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Had a stroke; This is a spontaneous case from a contactable consumer (Relative). A male patient of unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/lot number: unknown, Expiry Date: unknown) via unspecified route of administration as Unknown dose, single for COVID-19 immunization. The patient's Medical history and concomitant medications were not reported. It was reported that the patient had no history of stroke prior to the vaccine. After receiving the Pfizer vaccine, the patient experienced a stroke and continued to have some afterwards. He was Hospitalized overnight. The outcome for the event was Unknown.   Information about lot/batch number has been requested.
This spontaneous report as received from a physician via company representative refers to three patients of unknown demographics. The reporting physician stated that over the course of the last three years, on unspecified date three patients were vaccinated with ZOSTAVAX (lot #, route of administration, expiration date, dose not provided), and later, on unspecified date developed full-on shingles. At the time of vaccination all three patients were 65 years of age or older. The outcome of the event for all three patients was reported as recovered from shingles (date of recovery not provided). The relatedness between the event and vaccination with ZOSTAVAX was not reported. This case is liked to MARRS# 1404USA002472 (same reporter link). Additional information has been requested.
W/I 24 hours of immunization with Tdap - temp 100.2, local swelling and redness.